The SCS travel grant allowed me to attend the American College of Cardiology meeting in Washington in March 2017. I presented a poster detailing my research study “Is it safe to use high-sensitivity cardiac troponin T to rule out myocardial infarction at presentation?”
I studied 2577 consecutive patients admitted with suspected ACS who had serial troponin samples taken. 636 patients had an initial concentration <5ng/L at presentation. Only 5 of these patients went on to have a significant rise in their peak sample. 4 out of the 5 patients presented <3 hours of presentation. I was able to demonstrate a negative predictive value of 99.2% for myocardial injury if initial concentration is <5ng/L on presentation thus identifying 25% of patients who may suitable for immediate discharge.
The timing of the meeting was important; the same high-sensitive cardiac troponin T assay used in my study (Roche) has just been approved for use in USA. This is the only high-sensitivity assay to be approved for clinical use in USA so there was some interest in my study. This was a fantastic opportunity to share my work and meet colleagues with an interest in this area. I have had several clinicians contact me since the ACC meeting to enquire about my study and there is a potential collaboration on my next study with a renowned group from Minneapolis who have published widely in the area of cardiac markers.
The conference was informative and enjoyable. I would not have been able to attend if I had not been given this support from SCS.
Cardiology Nurse Consultant
I was awarded the SCS travel award at the 2016 autumn meeting for presenting my work on Tako-tsubo cardiomyopathy as part of my PhD.
The award allowed me to travel to Washington DC in February 2017 to attend the Society of CMR annual congress, where I was able to present my work on MR spectroscopy in TTC for an early career award. Attending the congress not only gave me the opportunity to present to an international audience but allowed me to meet with other researchers in the field of Cardiac MRI and develop contacts for future collaborations.
The congress itself was informative with clinical and case based sessions as well as new and original research.
Attending the clinical and case based sessions has allowed me to apply for Level 1 CMR accreditation and has advanced my knowledge of clinical CMR, the session on MR Physics for medics was especially useful to simplify the important physics concepts that I had been struggling with.
Without the award from the SCS it would have been difficult for me to attend the congress as a clinical research fellow with limited funds available for travel.
Dr Caroline Scally
Cardiology StR and BHF Clinical Research Fellow
The SCS travel award enabled me to attend the Society for Cardiovascular Magnetic Resonance annual congress in Washington, where I was able to present my preclinical work in Manganese-enhanced MRI. The study investigates Manganese-enhanced MRI and conventional Gadolinium contrast agents in a rodent model of myocardial infarction progressing to ischaemic cardiomyopathy. Our objectives were to compare both agents in myocardial infarction, and assess the capability of Manganese-enhanced MRI to detect dysfunctional calcium-handling in ischaemic cardiomyopathy using T1 mapping. We demonstrated Manganese agents as superior to Gadolinium for defining infarct size, and observed altered calcium handling at different time-points in ischaemic cardiomyopathy. This has relevance to future clinical translational studies in pathophysiology of cardiomyopathy.
The conference provided a valuable opportunity to present my work and discuss ideas for future directions with colleagues from other centres internationally, as well as to publicise this emerging field in MRI. In addition, the pre-conference workshop consisted of a valuable series of talks and seminars on CMR physics, orientated to clinicians. Other talks were highly informative on a breadth of preclinical and clinical topics in cardiovascular MRI.
I am very grateful for the support from the Scottish Cardiac Society in enabling me to attend this international meeting.
Clinical Research Fellow, Cardiology
University of Edinburgh
The European Society of Cardiology Acute Cardiovascular Care Association (ACCA) Congress was held in Lisbon, Portugal from the 14th to 17th October 2016. This congress is focused on acute cardiac pathology, and of interest to our research group, there were two sessions on the diagnosis of type 2 myocardial infarction and myocardial injury, chaired by the lead author of the Universal Definition of Myocardial Infarction, Prof Kristian Thygesen (Aarhus, Denmark).
I attended to present results from a cohort study into the long term outcomes of patients with type 2 myocardial infarction or myocardial injury. Whilst these conditions are distinct entities in clinical guidelines, they are poorly understood, and there are no recommendations for the investigation or management of these patients.
We found patients with type 2 myocardial infarction or myocardial injury were at much higher risk of all-cause mortality at five years, and similar risk of future adverse cardiovascular events to those with type 1 myocardial infarction. Interestingly, those with type 2 myocardial infarction or myocardial injury who had underlying coronary artery disease were at significantly increased risk of future adverse outcomes. We have now formally suggested the presence of coronary artery disease be considered in these patients, and are hopeful this will be considered in the next iteration of the Universal Definition of Myocardial Infarction.
Notably, former Scottish Cardiac Society prize winner Dr Anoop Shah (ST5, S.E Scotland) gave a lecture on the appropriate use of cardiac troponin testing in those with suspected acute coronary syndrome. Dr Shah was awarded the ESC ACCA Research Prize in recognition of his presentation and outstanding achievements in this field.
I would recommend the ACCA Congress for any cardiology trainees keen to improve their knowledge of the investigation or management of acute cardiac pathology. This year there were a number of training workshops on specific clinical scenarios, including acute pacemaker/ICD troubleshooting for the general cardiologist. This is also an excellent opportunity to engage with other European researchers, with an evening reception held for trainees, complete with complimentary refreshments, which (perhaps unsurprisingly) was well attended.
The next ACCA Congress is in Milan 2018, with two smaller events planned for 2017. I am grateful to the Scottish Cardiac Society for supporting my attendance at this valuable meeting.
Dr Andrew Chapman
Clinical Research Fellow (Cardiology)
University of Edinburgh